This finding is reflected by larger tumors, higher grade, advanced stage, more lymph node metastases, a higher prevalence of human epidermal growth factor receptor (HER)2 over-expression, and estrogen receptor (ER) negativity in young women with breast cancer [4, 5, 7]. This evidence concerns the gene ESR1 and breast carcinoma.